Adverse Events Module

Adverse Events Module

For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.

Adverse Events Module path is as follows:

Study -> Results Section -> Adverse Events Module -> Event Groups

Study -> Results Section -> Adverse Events Module -> Serious Events

Study -> Results Section -> Adverse Events Module -> Other Events

Adverse Events Module


Ignite Creation Date: 2025-12-25 @ 3:24 AM
Ignite Modification Date: 2025-12-26 @ 2:03 AM
NCT ID: NCT03303105
Description: Safety Set (SS): Newly enrolled subjects who received the IMP at least once
Frequency Threshold: 5
Time Frame: Baseline (Day 0) up to follow-up visit (Day 562)
Study: NCT03303105
Study Brief: Long-term Safety and Tolerability of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine
Event Groups(If Any):

Event Groups

Title Description Deaths # Affected Deaths # At Risk Serious # Affected Serious # At Risk Other # Affected Other # At Risk View
TEV-48125 (225 mg/1 Month) Group TEV-48125 will be administered subcutaneously once every 4 weeks for a total of 13 doses (at 225 mg once monthly \[except for a loading dose of 675 mg in subjects with chronic migraine). 0 None 0 25 20 25 View
TEV-48125 (675 mg/3 Month) Group TEV-48125 will be administered subcutaneously once every 12 weeks for a total of 5 doses (at 675 mg once every 3 months). 0 None 2 25 16 25 View
Serious Events(If Any):

Serious Events

Term Type Organ System Vocab View
Rhegmatogenous retinal detachment NON_SYSTEMATIC_ASSESSMENT Eye disorders MedDRA Ver. 22.0 View
Subarachnoid haemorrhage NON_SYSTEMATIC_ASSESSMENT Nervous system disorders MedDRA Ver. 22.0 View
Other Events(If Any):

Other Events

Term Type Organ System Vocab View
Injection site pruritus NON_SYSTEMATIC_ASSESSMENT General disorders MedDRA Ver. 22.0 View
Injection site induration NON_SYSTEMATIC_ASSESSMENT General disorders MedDRA Ver. 22.0 View
Injection site erythema NON_SYSTEMATIC_ASSESSMENT General disorders MedDRA Ver. 22.0 View
Influenza NON_SYSTEMATIC_ASSESSMENT Infections and infestations MedDRA Ver. 22.0 View
Gastroenteritis NON_SYSTEMATIC_ASSESSMENT Infections and infestations MedDRA Ver. 22.0 View
Oral herpes NON_SYSTEMATIC_ASSESSMENT Infections and infestations MedDRA Ver. 22.0 View
Back pain NON_SYSTEMATIC_ASSESSMENT Musculoskeletal and connective tissue disorders MedDRA Ver. 22.0 View
Cough NON_SYSTEMATIC_ASSESSMENT Respiratory, thoracic and mediastinal disorders MedDRA Ver. 22.0 View
Dysmenorrhoea NON_SYSTEMATIC_ASSESSMENT Reproductive system and breast disorders MedDRA Ver. 22.0 View
Injection site pain NON_SYSTEMATIC_ASSESSMENT General disorders MedDRA Ver. 22.0 View
Nasopharyngitis NON_SYSTEMATIC_ASSESSMENT Infections and infestations MedDRA Ver. 22.0 View